Description
AZD5991 is a higly selective Mcl-1 inhibitor, causing rapid tumor regression in mouse xenograft models.
AZD5991
Product ID A985136
Cas No. 2143061-81-6
Purity ≥99%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 2143061-81-6 |
|---|---|
| Purity | ≥99% |
| Formula | C35H34ClN5O3S2 |
| Formula Wt. | 672.26 |
| IUPAC Name | 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(36),4(38),6,11,14,16,18,20,23,29(37),30,32,34-tridecaene-23-carboxylic acid |
| Synonym | AZD-5991 |
| Appearance | White crystalline powder |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| Info Sheet |
|---|
References
Liu S, Qiao X, Wu S, et al. c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. Apoptosis. 2022 Dec;27(11-12):913-928. PMID: 35943677
Goliaei A, Woods H, Tron A, et al. Multiscale model identifies improved schedule for treatment of acute myeloid leukemia in vitro with the Mcl-1 inhibitor AZD5991. CPT Pharmacometrics Syst Pharmacol. 2020 Oct;9(10):561-570. PMID: 32860732
Tron A, Belmonte M, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018 Dec 17;9(1):5341. PMID: 30559424